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We conducted a study of patients with multiple myeloma (MM) undergoing allogeneic transplantation to
evaluate outcome parameters. Fifty-seven consecutive patients with MM received an allogeneic trans-
plantation between 2004 and 2011 at our institution. Patients who had received at least 1 prior autologous
transplantation were included. Twenty-six patients underwent allogeneic transplantation for consolidation
after a response to their ﬁrst autograft, and 30 patients received an allogeneic transplantation as salvage
therapy. Donor source was evenly distributed between related and unrelated. The median follow-up was
52 months. Thirty-two (57.1%) patients achieved a complete response (CR). At 5 years, 49.2% of all patients
were in CR. Sixteen patients received either donor lymphocyte infusions or immune suppression withdrawal
for disease progression, with a 62.5% response rate. The 5-year overall survival (OS) for all patients was 59%.
The 5-year OS for the 30 patients in the consolidation group was 82% compared with 38% for those in the
salvage group. In multivariate analysis, 3 factors remained signiﬁcantly associated with OS. These include
being in the salvage group (hazard ratio [HR], 4.05; P ¼ .0196), acute graft-versus-host disease (aGVHD) (HR,
2.99; P ¼ .034), and chronic graft-versus-host disease (cGVHD), which was highly protective, with a 5-year OS
of 78.8% for patients with cGVHD versus 42.6% for patients without cGVHD (HR .17, P ¼ .008). Our data show
that allogeneic transplantation for MM can lead to sustained remissions. aGVHD is signiﬁcantly deleterious to
OS and progression-free survival, whereas cGVHD is strongly favorable, supporting an important role for the
graft-versus-myeloma effect.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION developed, and treatment-related mortality has signiﬁcantly
Over the past decade, outcomes for patients withmultiple
myeloma (MM) have signiﬁcantly improved. The incorpora-
tion of novel therapies, proteasome inhibitors (bortezomib
[1] and carﬁlzomib [2]) and immunomodulatory agents
(lenalidomide [3] and pomalidomide [4]), have improved the
5-year survival from 29% to 43% [5]. Autologous trans-
plantation remains a standard treatment. MM is the most
common indication for autologous transplantation in North
America and the number of autologous transplantations has
been steadily increasing over the past decade, including
in older patients [6]. Allogeneic transplantation has been
receivedwith less enthusiasm,mainly because of its inherent
treatment-related mortality. Originally, allogeneic trans-
plantation was applied in the context of very advanced dis-
ease and involved the use of toxic myeloablative regimens,
leading to a treatment-related mortality ranging from 20%
to 40% [7]. Since then, there has been improvement in
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14.04.027decreased [8]. Large United States and European trials have
explored the role of allogeneic transplantation using non-
myeloablative (NMA) regimens in tandem with a prior
autologous transplantation [9,10]. The United States trial did
not show improvement over tandem autologous trans-
plantation at a median of 3 years follow-up. In contrast, the
European trial failed to show improvement at 3 years but did
show superiority of allogeneic transplantation with a 5-year
median follow-up. Thus, important questions remain, such
as the characteristics predicting survival and the role of the
graft-versus-myeloma effect. We report on the outcome of
57 patients with MM who received an allogeneic trans-
plantation at our institution.
PATIENTS AND METHODS
Patients
The study cohort included 57 consecutive patients with MM who
received an allogeneic hematopoietic stem cell transplantation (HSCT) be-
tween November 2004 and June 2011. For the purpose of this analysis, only
patients who had received at least 1 prior autologous transplantation were
included. All patients signed informed consents approved by our institu-
tional review board for data analysis, reporting, and transplantation.
Preparative Regimens
Patients received either an NMA, a reduced-intensity conditioning (RIC),
or a myeloablative (MA) regimen. Regimen selectionwas based on physician
preference, protocol, or treatment plan availability and eligibility at the timeTransplantation.
Table 1
Demographic Characteristics
Variable Value
No. of patients 56
Sex, female 26 (46.4)
Age, median (range), yr 52.4 (35-66)
Age  55 yr, n (%) 24 (42.9)
Disease
IgG 34 (61.8)
IgM 1 (1.8)
Light chain only 10 (18.2)
IgA 9 (16.4)
IgD 1 (1.8)
Nonsecretory 1 (1.8)
Disease status and treatment
PD, MR at time of allo HSCT 20 (35.7)
PR, VGPR, CR at time of allo HSCT 36 (64.3)
Salvage (less than PR or relapsed
disease to prior autograft)
30 (64.3)
Two prior autologous HSCTs 11 (19.6)
Donor
Sibling 35 (62.5)
MUD 11 (19.6)
MMUD 10 (17.9)
Preparatory Regimen
Myeloablative 10 (17.9)
Reduced-intensity conditioning 22 (39.3)
Nonmyeloablative 24 (42.9)
Cytogenetics
Unavailable 11 (19.6%)
Poor risk 16 (28.5%)
Normal/favorable 29 (51.8%)
PD indicates progressive disease; MR, minor response; allo, allogeneic;
VGPR, very good partial response; MUD, matched unrelated donor; MMUD,
mismatched unrelated donor.
Data presented are n (%), unless otherwise indicated.
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irradiation 200 cGy as a single dose for those with sibling donors adminis-
tered on day 0, and low-dose total body irradiation 200 cGy on day 0 with
ﬂudarabine 30 mg/m2 on days 5 to 3 for those with unrelated donors.
The RIC regimen consisted of ﬂudarabine 30 mg/m2 on days 5 to 3
(6 to 3 for those with unrelated donors) and melphalan 140 mg/m2 on
day 2, with the addition of low-dose thymoglobulin 4 mg/kg in divided
doses on days 3 to 1 for those with unrelated donors. The MA regimen
was intravenous busulfan 130 mg/m2 on days 7 to 4 and melphalan
70 mg/m2 on days 2 and 1, with thymoglobulin 4 mg/kg in divided doses
on days -3 to -1 for those with unrelated donors. All regimens have been
previously described in the literature [9,11-13]. Graft-versus-host disease
(GVHD) prophylaxis consisted of tacrolimus and mini-methotrexate [14]
or cyclosporine and mycophenolate mofetil [15] for patients receiving
NMA. Patients received antibiotic prophylaxis with valacyclovir, cipro-
ﬂoxacin and either ﬂuconazole or voriconazole. Pneumocystis jiroveci pro-
phylaxis was administered after engraftment. Patients did not receive
post-transplantation maintenance therapy.
Deﬁnitions and Terminology
The International Uniform Response Criteria for MMwere used to deﬁne
response, relapse, and progression [16]. Chronic GVHD (cGVHD) diagnosis
and staging were based on the 2005 NIH concensus [17]. Patients were
considered to have received allogeneic transplantation as consolidation if
they had at least a partial remission (PR) to their ﬁrst autograft and had not
progressed before the allograft. Salvage transplantation was deﬁned as
allogeneic transplantation after disease progression or less than a PR after
the ﬁrst autologous transplantation.
Statistical Method
Continuous variables were summarized as mean or median (inter-
quartile range), depending upon whether the data followed the normal
distribution or not. Comparisons of continuous variables between any 2
groups were conducted using a 2-sided t-test or 2-sidedWilcoxon rank-sum
test, as appropriate. Categorical variables were examined using Fisher exact
test or Pearson’s chi-square test, as appropriate. The endpoints of interest
included progression-free survival (PFS), overall survival (OS), incidence of
cGVHD, incidence of relapse, and incidence of nonrelapse mortality (NRM).
PFS was the time measured from the date of allogeneic transplantation
to disease progression, death, or last contact. Overall survival was measured
from the date of allogeneic transplantation to death from any cause. PFS and
OS were estimated using the Kaplan-Meier method. The cumulative inci-
dence of cGVHD was estimated with relapse and death as competing risks.
Chronic GVHD was also analyzed as a time-dependent variable. NRM was
considered a competing risk for incidence of relapse. Comparisons of PFS
and OS between groups were performed using a 2-sided log rank test. Ex-
aminations of association between progression and all cause of death and
potential risk factors were performed by ﬁtting the Cox proportional hazard
regression model. The assumption of proportional hazard was examined for
each factor. The results of Cox regression analyses are presented as hazard
ratio (HR), 95% conﬁdence interval (CI) for HR, and P value. Any P < .05 was
considered statistically signiﬁcant. Cumulative incidence curve estimates for
cGVHD and NRMwere done using package cmprsk in R-2.15.2 (R foundation
for Statistical Computing, Vienna, Austria). All other data were analyzed
using SAS version 9.2 (SAS Institute Inc. Cary, NC).
RESULTS
Patient Characteristics
We identiﬁed 57 patients with MM who underwent
allogeneic hematopoietic stem cell transplantation between
November 9, 2004 and June 1, 2011. One patient under-
went allogeneic transplantation without a prior autologous
transplantation. We excluded this patient for the data
analysis. Eight patients were participants in the The Blood
and Marrow Transplant Clinical Trials Network (BMT CTN)
0102 study. All patients met program criteria for selection of
allogeneic transplantation candidates, deﬁned in our stan-
dard operating procedures. We identiﬁed a favorable group
of 26 patients who received allogeneic transplantation for
consolidation after demonstrating a least a PR to their ﬁrst
autograft and without evidence of progression, leaving 30
patients in the salvage transplantation group, deﬁned as
patients with less than a PR or in relapse after their
ﬁrst autograft. Eleven patients had received 2 priorautologous transplantations. A summary of the patients’
characteristics is presented in Table 1.
The median age was 52.4 years (range, 35 to 66). Twenty
patients (35.7%) had either progressive disease or a minor
response to their last treatment before allogeneic trans-
plantation. The hematopoietic cell donors were 35 siblings
and 21 unrelated. Only 1 patient received bone marrow as
source of stem cells; all others received peripheral blood. In
the unrelated donor group, 10 (47.6%) patients had a mis-
matched (<10/10 HLAmatch) donor. In our cohort, 10 (17.9%)
patients receivedMA, 22 (39.3%) received RIC, and 24 (42.9%)
received NMA regimens. The median follow-up was
52 months (range, 23.6 to 84). The related and unrelated
donor cohorts were similar for all demographic characteris-
tics except for age (53.9 versus 49.8 years, P ¼ .03).
Response and Relapse
Overall, 32 (57.1%) patients achieved a complete remis-
sion (CR); this includes the 4 patients who started their
transplantation in a CR. Seven (12.5%) patients had a very
good partial remission, 13 (23.2%) had a PR, and 2 (3.6%) had
stable disease. Two patients were not assessable for
response. At a median follow-up of 52 months, 49.2% of pa-
tients were in CR; this includes patients who obtained a CR
after donor lymphocyte infusions (DLI) given for disease
progression.
Twenty-one (37.5%) patients progressed after allogeneic
transplantation and 16 of those received either DLI (15 pa-
tients) or immune suppression withdrawal (1 patient). The
response rate to these interventions was 62.5% (10 patients).
Of the 10 responders, which included the patient who had
immune suppression withdrawal, 9 developed cGVHD. All
but 1 of the responses were sustained. The current 5-year
Figure 1. Overall survival for all 56 patients.
Figure 2. Overall survival, consolidation group versus salvage group.
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tained response to DLI or immune suppressionwithdrawal, is
62% for the entire cohort.
GVHD
The cumulative incidence of acute GVHD (aGVHD) grades
II to IV was 35.4%; 28.6% for those with related donors and
47.6% for those with unrelated donors (P ¼ .16). Patients
receiving an NMA regimen had less aGVHD (P ¼ .006),
including less grade III to IV aGVHD (P ¼ .0011). Other risk
factors for the development of aGVHD include trans-
plantation done as consolidation versus salvage (P ¼ .0048)
and disease status before transplantation, PR, or better
versus less than PR (P ¼ .041), with patients entering allo-
geneic HSCT with better disease control having less aGVHD.
The cumulative incidence of cGVHD was 50%; 52% for
those with related donors and 43% for those unrelated do-
nors (P ¼ not signiﬁcant). Overall, 28.6% of patients devel-
oped moderate or severe cGHVD, with no difference
between the unrelated or related donor groups or prepar-
ative regimens.
Potential factors associated with the risk of cGVHD were
examined. Multivariate analysis considering age, gender,
disease status, donor type, regimens, number of trans-
plantations, and aGVHD identiﬁed only severe aGVHD (grade
III to IV) as signiﬁcantly associated with increase incidence of
cGVHD (HR, 5.29; 95% CI, 1.30 to 21.51). The potential impact
of antithymocyte globulin (ATG) on the development of
GVHD could not be assessed as only patients receiving un-
related donor products were given ATG as part of the pre-
parative regimen.
NRM
The number of nonrelapse deaths was 13 (23.2%). The
causes of deaths were GVHD (7 patients), infection (4 pa-
tients), and graft failure (2 patients). The cumulative inci-
dence of NRM at 1 year was 18.2%. Analysis indicated that
although relapsed or refractory disease to the ﬁrst autolo-
gous transplantation and disease status at time of the allo-
geneic transplantation were signiﬁcantly associated with OS
and PFS, these factors had no impact on NRM. The prepara-
tive regimen also had no statistically signiﬁcant impact on
NRM. However, in the multivariate model, 2 prior autologous
transplantations and grades III and IV aGVHD were signiﬁ-
cantly associated with increased NRM.
OS and Prognostic Features
The OS for all 56 patients was 59% at 5 years (Figure 1).
The 5-year OS for the 30 patients who received trans-
plantation as salvage was 38% compared with 82% for the
consolidation group (Figure 2). Univariate associations be-
tween potential prognostic factors and risk of death from any
cause are presented in Table 2. The univariate analysis in-
dicates that patients receiving their allogeneic trans-
plantation as salvage, disease status before allogeneic HSCT,
number of prior autologous HSCT, NMA regimen, aGVHD,
response to the allogeneic HSCT, and cGVHD were signiﬁ-
cantly associated with the OS, with cGVHD being protective.
Notably, donor type (unrelated versus related), cytogenetics,
and age were not signiﬁcant predictors. Adverse cytogenetic
aberrations were evenly distributed; 8 patients in each the
consolidation and salvage groups, with no statistical signiﬁ-
cance in either group.
These prognostic factors were considered in a multivar-
iate analysis. The results are shown in Figures 2, 3, and 4.Three factors remained signiﬁcantly associated with OS.
These include being in the salvage group (HR, 4.05; 95% CI,
1.25 to 13.11; P¼ .0196), aGVHD (HR, 2.99; 95% CI, 1.09 to 8.2;
P¼ .034), and cGVHD, which is protective (HR, .26, 95% CI, .09
to .75; P ¼ .012). When treated as a time-dependent covari-
ate, cGVHD remained statistically signiﬁcant (HR, .17; 95%
CI, .47 to .63; P ¼ .008). Patients with cGVHD had a 36.2%
survival advantage at 5 years compared with patients with-
out cGVHD.PFS and Prognostic Features
The PFS for all 56 patients was 38% at 5 years. Patients in
the consolidation group and the salvage group had 5-year
PFS of 57% and 21%, respectively. Similarly to OS, univariate
analysis demonstrated that relapsed or refractory disease to
ﬁrst autologous HSCT (consolidation versus salvage group),
disease status at the time of the allogeneic HSCT, number of
prior autologous of HSCT, aGVHD, response after allogeneic
HSCT, and cGVHDwere signiﬁcantly associated with PFS. The
preparative regimen was not associated with PFS.
A multivariate analysis was performed, identifying dis-
ease status at the time of allogeneic HSCT (HR, .36; 95% CI, .16
to .83; P ¼ .0164) and aGVHD (HR, 5.85; 95% CI, 1.99 to 17.19;
P ¼ .0013) as signiﬁcantly associated with PFS. When
considered as a time-dependent covariate, cGVHD was
signiﬁcantly associated with a reduced risk of disease pro-
gression (HR, .35; 95% CI, .15 to .77; P ¼ .0097).
Figure 4. Overall survival, patients with or without cGVHD.
Table 2
Association with Risk of All-Cause Mortality (Overall Survival) in Univariate
Analysis
Variable HR 95% CI P Value
Sex (ref: male), female 1.069 .463-2.468 .8766
Age group (ref: age < 55 yr),
age  55 yr
1.074 .464-2.488 .8673
Disease
Relapse/refractory to ﬁrst
auto HSCT (ref: no), Yes
5.569 1.878-16.515 .0020
Disease status at allo HSCT
(ref: PD, MR), PR, VGPR, CR
.261 .111-.613 .0020
Cytogenetics (ref:
good/intermediate), poor
1.826 .648-5.148 .2547
Post-allo HSCT relapse/
progression (ref: no), yes
1.297 .560-3.005 .5439
Donor
URD (ref: no), yes 1.603 .692-3.714 .2710
HLA-match (ref: sib), MMUD 1.821 .641-5.175 .2608
HLA-match (ref: sib), MUD 1.432 .504-4.068 .5003
GVHD
aGVHD (ref: none), yes 4.802 1.993-11.569 .0005
aGVHD (ref: none), grade I 4.828 1.013-23.014 .0481
aGVHD (ref: none), grade II 2.903 .947-8.901 .0623
aGVHD (ref: none), grade III 8.524 2.675-27.170 .0003
aGVHD (ref: none), grade IV 32.130 5.388-191.61 .0001
cGVHD (ref: none), yes .229 .084-.626 .0041
cGVHD (ref: none),
moderate or severe
.306 .102-.919 .0349
cGVHD (ref: none), mild .114 .015-.861 .0353
Treatment
Two prior auto HSCT
(ref: 1 prior auto)
9.210 3.643-23.283 <.0001
Preparatory regimen
(ref: NMA), MA
4.665 1.467-14.832 .0091
Preparatory regimen
(ref: NMA), RIC
3.139 1.057-9.325 .0394
Ref indicates reference category; auto, autologous; URD, unrelated donor.
Risk of all-cause mortality was examined by Cox proportional hazard
regression model.
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The role of allogeneic transplantation in the management
of MM remains to be determined. To date, 3 randomized
trials have compared tandem autologous transplantation
versus autologous followed by allogeneic transplantation.
The basis of the randomization for all of these studies was
the availability of a matched sibling donor. The Italian trial
showed improvement in PFS and OS for the autologous-
allogeneic group [18]. The BMT CTN 0102 phase III trialFigure 3. Overall survival, patients with or without aGVHD.enrolled 710 patients from centers across the United States
[9]. Patients with an HLA-identical sibling received an
NMA allogeneic transplantation, as a tandem autologous-
allogeneic transplantation. The study was published after
3 years of follow-up and showed no difference in OS (77%
versus 80%) or PFS (43% versus 46%) between the autologous-
allogeneic group and the tandem autologous group. More
recently, long-term results of the European Group for Blood
and Marrow Transplantation Non-Myeloablative Allogeneic
stem cell transplantation in Multiple Myeloma (EBMT-
NMAM2000) study were reported [10], updating the initial
study results published 2 years earlier [19]. In this study, 357
patients with MM were biologically randomized to either
autologous followed by allogeneic transplantation or autol-
ogous transplantation alone. Earlier results at the 3-year
interim analysis had failed to show a difference in OS or
PFS. However, with a median follow-up of 96 months, pa-
tients randomized to autologous followed by allogeneic
transplantation demonstrated signiﬁcantly superior OS (49%
versus 36%) and PFS (22% versus 12%). The survival curves
between the 2 groups start separating about 36 months after
transplantation. Based on this experience, longer follow-up
of BMT CTN 0102 is awaited to see if a similar observation
will be made.
The BMT CTN and EBMT-NMAM studies and others
have a randomization based on the availability of a sibling
donor, likely because of the fact that matched sibling trans-
plantations were previously considered safer than unrelated
donor transplantations. One of the initial unrelated donor
reports for MA allogeneic transplantations for MM had
dismal results, with only 9% survival at 3 years and a 100-day
mortality of 42% [20]. In more recent years, with the use
of high-resolution typing and RIC, unrelated donor trans-
plantation outcomes have, in many circumstances, been
comparable to matched siblings transplantations [21]. In a
single-center French study of 40 high-risk patients with MM,
no difference was found in the 2-year PFS (42% versus 44%)
and OS (59% versus 66%) between recipients of unrelated
versus related donors [22]. In our study, no signiﬁcant dif-
ference in outcome was observed between the related and
unrelated donor groups. Therefore, the decision to proceed
to allogeneic transplantation should not be based only on the
availability of a sibling donor.
Our consolidation group demonstrated an 82% 5-year
survival and this was signiﬁcantly superior to the salvage
group. Nonetheless, relapsed or refractory patients have
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The MD Anderson group recently reported on 51 heavily
pretreated patients with relapsed disease [23]. In their study,
the 2-year OS was 32%. The 30 patients in our salvage group
had a 5-year survival of 38%. This suggests that poor prog-
nostic patients with relapsed or refractory disease may be
salvaged with allogeneic transplantation. Second autologous
transplantation has also been used in the salvage setting, but
a randomized comparison of autologous versus allogeneic
transplantation for salvage has yet to be completed. A recent
nonrandomized comparison using Center for International
Blood and Marrow Transplant Research data of autologous
versus allogeneic transplantation in relapsed patients failed
to show superiority of the allogeneic group [24]. However
the 3-year PFS and OS of the allogeneic group were very poor
at 6% and 20%, respectively. Our institution previously re-
ported on 31 patients with relapsed or refractory multiple
myeloma who received a second autologous transplantation
using the melphalan, bortezomib, and thalidomide regimen
[25]. The 2-year PFS was only 5%. The PFS at 5 years for the
allogeneic salvage group reported here is 21%. Relevant to
this group, our multivariate analysis demonstrated that pa-
tients who had received 2 prior autologous transplantations
had an increase in NRM. This warrants consideration when
choosing a debulking strategy before proceeding to alloge-
neic transplantation. A second autologous transplantation
may be unadvisable based on this ﬁnding. Registry data from
the EBMT also demonstrated an increase in treatment-
related mortality after allogeneic transplantation for pa-
tients who had received 2 prior autologous transplantations
[26].
Forty-ﬁve of the 56 patients had standard karyotyping
and/or ﬂuorescent in situ hybridization performed at the
time of initial diagnosis, with results available for analysis.
Patients with t(11;14) and/or hyperdiploidy were consid-
ered to have favorable cytogenetics, whereas patients with
either t(4;16), t(4;14), þ1q21, del(17p13), and del(13q14),
the latter by standard karyotyping only, were consider-
ed to have unfavorable cytogenetics. These unfavorable
chromosomal aberrations have been previously shown to
negatively inﬂuence the outcome after autologous trans-
plantation [27]. A recent analysis of 12 chromosomal ab-
normalities found that, in a multivariate model, t(4;14)
and del(17p13) have a negative impact on both PFS and OS
after autologous transplantation. The 5-year OS was 72%
for the favorable cytogenetics group and 41% for the un-
favorable group (P < .001) [28]. The impact of cytogenetics
in the context of allogeneic transplantation has been
reported and there is evidence that cytogenetic aberra-
tions may not inﬂuence outcome [29]. We were unable to
demonstrate a worse outcome in our 16 patients with
adverse cytogenetics. Whether allogeneic transplantation
may overcome the negative prognostic effects of high-risk
cytogenetics still remains to be evaluated in a larger pa-
tient population.
A graft-versus-myeloma effect has been previously re-
ported. Chronic GVHD has been demonstrated as being
favorable for OS and PFS [26,30]. The Italian Bone Marrow
registry data of 196 patients with MM receiving an unrelated
donor transplant showed a signiﬁcant improvement in OS for
patients with cGVHD (HR, .55) [30]. Similarly, an analysis of
prognostic factors from the Chronic Leukaemia Working
Party of the EBMT on the outcome of 229 patients with MM
receiving an allograft demonstrated that cGVHD was asso-
ciated with better OS and PFS [26]. In our multivariateanalysis, cGVHD was a highly signiﬁcant factor inﬂuencing
patient outcome with a marked improvement in OS (HR,
.264), conferring a 36.2% survival advantage at 5 years for
patients with cGVHD.
Response to DLI is often seen as proof of the graft-versus-
tumor effect. Beitinjaneh et al. [31] reported on 162 patients
with MM who received an allogeneic HSCT, 23 of whom
received donor lymphocytes for residual or relapsing disease.
The rate of achieving at least a very good partial response to
donor lymphocytes was 22%, with a median duration of
response of 21.8 months. Analysis of EBMT registry data on
DLI for myeloma reports a response rate of 63% in a series of
70 patients when given preemptively and 52% when given
for relapsed disease [26]. Our response rate to DLI of 62.5%
supports this approach for treatment of progressive disease
after allogeneic transplantation for MM. This again demon-
strates a signiﬁcant role for the graft-versus-myeloma effect.
In contrast, aGVHD is known as a major cause of treat-
ment-associated mortality. The Italian Bone Marrow Registry
of patients with myeloma receiving unrelated donor trans-
plants demonstrated an association between aGVHD and
a poorer OS in multivariate analysis [30]. Similarly, our
multivariate analysis shows the negative impact of aGVHD
on both OS and PFS, with all grades of aGVHD affecting all-
cause mortality. Grade III to IV aGVHD was associated with
a signiﬁcant increase in NRM. Based on our data, the early
invitation of aGVHD as preemptive immunomodulation ap-
pears to be ill advised. Strategies to prevent aGVHD in this
patient population are warranted.
In conclusion, our data demonstrate that allogeneic
transplantation for MM can lead to sustained remissions,
even in patients with relapsed or refractory disease. Patient
selection for allogeneic transplantation based on the avail-
ability of a sibling donor is not supported by our analysis. The
development of aGVHD is signiﬁcantly deleterious to both OS
and PFS, whereas cGVHD is strongly favorable, supporting an
important role for the graft-versus-myeloma effect.ACKNOWLEDGMENTS
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